Cue Biopharma Welcomes Tamar Howson to its Board of Directors
September 17, 2020 08:00 ET
|
Cue Biopharma, Inc.
Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE...
Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
September 15, 2020 08:00 ET
|
Cue Biopharma, Inc.
Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity ...
Cue Biopharma to Present at Upcoming Investor Conferences in September 2020
September 03, 2020 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
August 31, 2020 16:01 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit
August 24, 2020 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma to Host Business Update Call and Webcast
August 17, 2020 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer
July 28, 2020 08:00 ET
|
Cue Biopharma, Inc.
CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be...
Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily
July 08, 2020 08:00 ET
|
Cue Biopharma, Inc.
- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at...
Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer
June 15, 2020 08:00 ET
|
Cue Biopharma, Inc.
Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 doseDose-proportional...
Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference
May 28, 2020 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...